The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.

This short-term outlook edition coincides with the unfolding of the Covid-19 crisis, making the exercise exceptionally challenging. Market forecasts are based on market intelligence available at the beginning of April 2020 and reflect the Covid-19 impact to the extent possible, with all the caveats and limitations in view of the rapidly evolving situation. In addition, for the first time market outlooks are presented for EU-27, and assume a frictionless trade between the EU and the UK in 2020.